Highest-materiality recent filing
Hepion Pharmaceuticals appoints Danina Fisher and Gary S. Stetz, II to board
Danina Fisher and Gary S. Stetz, II appointed as directors effective July 1, 2026.
Hepion shareholders approve 40x increase in equity plan shares to 8M at annual meeting
Elected directors Stetz, V. LoPriore, Purcell, Appajosyula, C. LoPriore with ~13.5M votes each.
Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares
Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.
Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment
Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.
Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO
CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.
Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics
Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.
Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K
Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named
John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.
Hepion shareholders reject reverse stock split amendment at 2025 annual meeting
Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16
Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.
Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones
Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
Hepion delisted from Nasdaq; pivots to diagnostics via New Day license
Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.
Hepion in-licenses diagnostic tests from New Day Diagnostics for $0.725M upfront
In-licensed celiac, respiratory multiplex (COVID/flu A/B/RSV), H. pylori, and HCC tests; three have CE marks for EU sale.
Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29
Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.
Hepion files amended balance sheet to correct warrant accounting; $6.14M warrant liability recorded
Amended 8-K/A filed to correct accounting for Series A and B warrants issued in Jan 2025 offering.
Hepion receives Nasdaq delisting notice as bid price falls below $0.10 for 10 days
Stock closed below $0.10 for 10 consecutive business days triggering the Low Priced Stocks Rule.
Hepion Pharmaceuticals implements 1-for-50 reverse stock split effective March 17, 2025
Every 50 pre-split shares reclassified into 1 share; par value unchanged at $0.0001.
Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting
All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.
Hepion Pharmaceuticals provides unaudited balance sheet as of Jan 31, 2025; cash of $5.36M
Cash and cash equivalents of $5.36M as of January 31, 2025.
Notice dated January 14, 2025 from Nasdaq for failing to hold annual shareholders' meeting within 12 months of fiscal year end.
Hepion terminates merger with Pharma Two B; special meeting cancelled
Merger Agreement with Pharma Two B Ltd. terminated mutually on Dec 10, 2024.
Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.
Hepion Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Notice received Sept. 3, 2024; bid price below $1.00 for 30 consecutive business days.
Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over
John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.
Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.
Hepion appoints Michael Purcell to board as Audit Committee Chair
Michael Purcell appointed as director of Hepion Pharmaceuticals on March 5, 2024.
Chairman Gary Jacob resigns from Hepion board; John Brancaccio appointed Chairman
Dr. Gary Jacob resigned as Chairman and from the Board on February 20, 2024, for personal reasons.
Hepion raises $2.06M via warrant inducement, reduces exercise prices and issues new warrants
Holders of 980,393 Series B warrants will exercise at reduced price of $2.10/share, raising ~$2.06M gross proceeds.
Hepion Pharma Director Anand Reddi resigns from board effective Feb 7, 2024
Anand Reddi resigned from Board of Directors on Feb 7, 2024.
Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor
BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.
Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%
Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.
Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants
Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.
Hepion CMO Todd Hobbs resigns; Stephen Harrison appointed Consultant Medical Director
Dr. Todd Hobbs resigned as CMO effective September 29, 2023; resignation not due to any disagreement with the Company.
Hepion provides corporate presentation; no material new financial or clinical data
Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.
Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald
ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.
All seven director nominees elected; votes For ranged from 15.7M (Jacob) to 20.7M (Wijngaard).
Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).
Hepion Pharmaceuticals effects 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split ratio 1-for-20 effective 4:01pm ET May 10, 2023; split-adjusted trading begins May 11 under same symbol HEPA.
Hepion shareholders approve reverse stock split; Board to set ratio 1:2 to 1:20
Special meeting held Dec 15, 2022; proposal to amend charter for reverse split approved.
Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock
Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.
Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials
Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.
Hepion shareholders reject authorized share increase from 120M to 200M
Proposal received 19,267,720 For, 27,847,827 Against, 254,176 Abstain; broker non-votes 1.
Hepion appoints Anand Reddi and Kaouthar Lbiati to Board of Directors
Board expanded to 8; Reddi and Lbiati appointed independent directors effective June 27, 2022.
Proposal 3 (2022 Omnibus Equity Incentive Plan) failed: 11.0M for, 20.1M against.
Hepion receives Nasdaq delisting notice for bid price below $1.00 per share
Notice received June 3, 2022; stock continues trading under symbol HEPA.
Hepion reports positive Phase 2a AMBITION NASH data; plans three Phase 2/2b trials starting Q3 2022
Phase 2a AMBITION NASH trial met primary endpoints: safety, tolerability, PK; no serious adverse events.
Hepion Pharmaceuticals announces death of director Thomas Adams
Thomas Adams, Ph.D., passed away on January 9, 2022 due to natural causes.
Phase 2a NASH trial (AMBITION) met safety endpoints; showed ALT and Pro-C3 reductions over 28 days.
Hepion's lead NASH drug gets USAN name 'rencofilstat'
USAN Council adopted 'rencofilstat' as nonproprietary name for CRV431, Hepion's lead NASH/liver disease drug.
Hepion Pharma gets FDA IND clearance for CRV431 in liver cancer (HCC), enabling direct Phase 2 start
FDA accepted IND for CRV431 for hepatocellular carcinoma; allows Phase 2 trial to begin without Phase 1.
On June 3, 2025, the Board of Directors of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), approved the appointment of Dr. Kaouthar Lbiati, a director of the Company, as interim Chief Executive Officer, effective June 16, 2025.
On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.
On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.
On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) appointed Michael Purcell as a director of the Company.
Dr. Jacob was Chairman of the Company and the Board of Directors appointed John Brancaccio as Chairman.
On February 20, 2024, Dr. Gary Jacob resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) for personal reasons.
On February 7, 2024, Anand Reddi resigned from the Board of Directors of Hepion Pharmaceuticals, Inc.
the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.
Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately.
Dr. Peter Wijngaard resigned from the Board of Directors of the Company.
On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.
On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.
Max materiality 0.90 · Median 0.60 · Most common event other_material